In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xenon gets $58mm from Warner-Lambert in HDL cholesterol deal

Executive Summary

In a three-year deal, private Canadian genomics company Xenon Genetics has licensed its drug discovery technology to Warner-Lambert, which will get exclusive worldwide rights to any compounds identified to treat low HDL cholesterol levels. For the first product commercialized, W-L will pay Xenon $57.75mm ($Cdn87mm) in up-fronts, research funding, equity and milestones, and additionally will pay royalties on product sales.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies